• Abiraterone Acetate in Patient-Derived Models

  2026-10-05

  A translational analysis of Abiraterone acetate, CYP17 biology, and patient-derived prostate spheroids. The article separates pathway mechanism from observed phenotype, clarifies what organ-confined models can—and cannot—say about castration-resistant prostate cancer, and outlines evidence-led priorities for future research.

• Zolmitriptan: Evidence, Mechanism, and Research Context

  2026-10-05

  This overview distinguishes supplier-described pharmacology for Zolmitriptan from peer-reviewed evidence on fangchinoline and H1N1 infection. It examines receptor-focused research applications, compares evidence strength, and defines the limits of applying lysosomal antiviral findings to serotonin receptor pharmacology.

• Intestinal TM6SF2 and the Gut–Liver Axis in MASH

  2026-10-04

  A 2025 Nature Metabolism study identifies intestinal TM6SF2 as a protective regulator of MASH through effects on the gut barrier, microbiota and lysophosphatidic acid signaling. Its genetic, microbiome-transfer and pharmacological evidence supports a gut-to-liver disease mechanism, while the mouse models and intervention scope define important limits for translation.

• Cyanine 5-dCTP and the Next Era of DNA Synthesis

  2026-10-03

  Cyanine 5-dCTP is more than a fluorescent tag: it can serve as a molecular readout for enzymatic DNA synthesis, provided signal is separated from incorporation, fidelity, and accessibility. This article interprets DNA-framework evidence, defines translational validation questions, and positions Cy5-dCTP within the evolving landscape of fluorescent nucleic acid analysis.

• Flavopiridol: From CDK Arrest to ER Stress Insight

  2026-10-02

  Flavopiridol, also known as L868275, offers translational researchers a pharmacologic route to interrogate CDK-dependent proliferation, apoptosis, and transcription. This article connects its oncology applications with emerging evidence that unresolved endoplasmic reticulum stress can impair intestinal stem-cell function, while separating established findings from testable cross-domain hypotheses.

• Firefly Luciferase mRNA as a Route-Sensitive Reporter

  2026-10-01

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) enables sensitive, transient measurement of translation and delivery. This article explains how to interpret its signal across cellular assays, lipid nanoparticles, and emerging gastrointestinal delivery workflows.

• Evacetrapib and the Ferroptosis Translation Gap

  2026-10-01

  A translational framework linking H2S-mediated persulfidation, homocysteine metabolism, ferroptosis susceptibility, and the exploratory use of Evacetrapib (LY2484595) in lipid-context studies.

• Firefly Luciferase mRNA as a Translational Control

  2026-09-30

  A mechanistic and strategic guide to using Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) as a high-confidence control for delivery, expression, cell-state, and translational development studies.

• Niclosamide for ATRX-Aware Cancer Assays

  2026-09-30

  Niclosamide is examined here through an ATRX-aware assay framework that connects STAT3 pharmacology with genotype-dependent drug sensitivity in glioma research. The article separates established product evidence from testable hypotheses, helping researchers design stronger target-engagement, apoptosis, and cell-cycle experiments.

• L-Phenylephrine: Sex-Aware α1A Assay Design

  2026-09-29

  L-Phenylephrine enables controlled investigation of adrenergic α1A receptor signaling across vascular, cardiac, and neural models. This article translates sex-dependent hypertension findings into a rigorous framework for selecting endpoints, controls, and assay conditions without conflating a pressor probe with direct mechanistic proof.

• Tankyrase Inhibition and Hippo Signaling in HCC

  2026-09-29

  Jia et al. showed that the tankyrase inhibitors XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth while reducing YAP activity and increasing the Hippo-pathway regulators AMOTL1 and AMOTL2. The study’s main contribution is a mechanistic link between tankyrase inhibition and Hippo cascade modulation, extending interpretation beyond the canonical Wnt/β-catenin pathway.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows

  2026-09-28

  Build more reproducible inflammation, pain, and environmental toxicology assays with the pharmacologically active (S)-(+)-Ibuprofen enantiomer. This guide connects stereopure COX inhibition to practical dosing, controls, endpoint selection, and troubleshooting across research workflows.

• Abiraterone Acetate in Patient-Derived Prostate Models

  2026-09-28

  Abiraterone acetate is a CYP17 inhibitor for studying steroid supply and androgen signaling in prostate cancer research. This article examines how patient-derived spheroids can reveal model-specific drug responses—and why a negative result should prompt assay analysis rather than a sweeping conclusion.

• Protease Inhibitor Cocktail for Protein Assays

  2026-09-27

  Protect labile proteins during extraction while keeping divalent cations available for phosphorylation-sensitive and enzyme assays. This practical guide shows how to apply an EDTA-free, 100X DMSO cocktail to workflows inspired by recent atopic dermatitis hydrogel research—without implying the study tested this reagent.

• Purifying and Analyzing Mycobacterium tuberculosis WecA

  2026-09-26

  Zhao and colleagues report a regulated expression and affinity-purification workflow for Mycobacterium tuberculosis WecA, a difficult membrane enzyme involved in cell-wall biosynthesis. They establish an activity readout based on UMP detection and identify tunicamycin as a competitive inhibitor, providing a biochemical platform for further enzyme and inhibitor studies.

7934 records 1/529 page Next 12345 下5页 Last page